Show simple item record

dc.contributor.authorThaçi, D
dc.contributor.authorKimball, A
dc.contributor.authorFoley, P
dc.contributor.authorPoulin, Y
dc.contributor.authorLevi, E
dc.contributor.authorChen, R
dc.contributor.authorFeldman, SR
dc.date.accessioned2020-12-22T05:45:53Z
dc.date.available2020-12-22T05:45:53Z
dc.date.issued2017-03
dc.identifier.citationThaçi, D., Kimball, A., Foley, P., Poulin, Y., Levi, E., Chen, R. & Feldman, S. R. (2017). Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.. J Eur Acad Dermatol Venereol, 31 (3), pp.498-506. https://doi.org/10.1111/jdv.13918.
dc.identifier.issn0926-9959
dc.identifier.urihttp://hdl.handle.net/11343/258353
dc.description.abstractBACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis. OBJECTIVES: To evaluate the impact of apremilast on health-related quality of life (HRQOL), general functioning and mental health using patient-reported outcome (PRO) assessments among patients with moderate to severe plaque psoriasis in the ESTEEM 1 and 2 trials. METHODS: A total of 1255 patients were randomized (2 : 1) to apremilast 30 mg BID or placebo for 16 weeks; all received apremilast through Week 32. PRO assessments included the Dermatology Life Quality Index (DLQI), 36-Item Short-Form Health Survey version 2 mental/physical component summary scores (SF-36v2 MCS/PCS), Patient Health Questionnaire-8 (PHQ-8), EuroQol-5D (EQ-5D) and Work Limitations Questionnaire-25 (WLQ-25). Post hoc analyses examined relationships between Psoriasis Area and Severity Index (PASI) scores and PHQ-8 in the apremilast-treated population at Week 16. RESULTS: Treatment with apremilast improved all HRQOL PROs at Week 16 (vs. placebo), except the SF-36v2 PCS, and improvements were sustained through Week 32. Mean DLQI and SF-36v2 MCS improvements exceeded minimal clinically important differences. Changes at Week 16 in PHQ-8 and PASI were weakly correlated, and only 35.8% of patients who achieved a ≥75% reduction from baseline in PASI score (PASI-75) with apremilast treatment also achieved PHQ-8 scores of 0-4. CONCLUSIONS: Apremilast led to improvements in HRQOL PROs vs. placebo in patients with moderate to severe plaque psoriasis.
dc.languageeng
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleApremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
dc.typeJournal Article
dc.identifier.doi10.1111/jdv.13918
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleJournal of the European Academy of Dermatology and Venereology
melbourne.source.volume31
melbourne.source.issue3
melbourne.source.pages498-506
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1193451
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363239
melbourne.contributor.authorFoley, Peter
dc.identifier.eissn1468-3083
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record